MAPK1 siRNA/nanocarrier complex used in a model of glomerulonephritis demonstrated that MAPK1 suppression remarkably improved kidney function, reduced proteinuria, and ameliorated glomerular sclerosis. Here, MAPK1 is linked to glomerulosclerosis.